ELIAS Animal Health

📢 ELIAS at VCS/VSSO 2026 Collaborative Conference — Don’t Miss The New Data!

ELIAS Animal Health is proud to be sharing new survival data from the ASCENT study, which is evaluating the combination of ELIAS Cancer Immunotherapy (ECI®) and carboplatin chemotherapy to treat bone cancer in dogs.

The oral abstract, "One-Dose Carboplatin Followed by Vaccine-Enhanced Adoptive Cell Therapy (ECI®) Improves Outcomes Compared to Four-Dose Carboplatin in Dogs With Osteosarcoma – 18-Month Update," will be presented by Dr. Jeffrey Bryan, University of Missouri, on Saturday, March 21.

We look forward to connecting with veterinary oncologists and surgeons in March! If you're attending the conference, stop by our booth to discuss how to incorporate ECI® into your clinical practice.